Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused >2.7 million deaths worldwide,1 devasting health systems end economies worldwide. Since the first months of the pandemic, a rapid and massive effort has been performed by the scientific community to develop a safe a...
Gespeichert in:
| Veröffentlicht in: | Infection control and hospital epidemiology 2021-11, Vol.42 (11), p.1390-1391, Article 0899823 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1391 |
|---|---|
| container_issue | 11 |
| container_start_page | 1390 |
| container_title | Infection control and hospital epidemiology |
| container_volume | 42 |
| creator | Damiani, Verena Mandatori, Domitilla De Fabritiis, Simone Bibbo, Sandra Ferrante, Rossella Di Giuseppe, Fabrizio Ruggieri, Anna Giulia Di Camillo, Carola Buccolini, Carlotta Pizzi, Dora Fazii, Paolo Stuppia, Liborio De Laurenzi, Vincenzo |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused >2.7 million deaths worldwide,1 devasting health systems end economies worldwide. Since the first months of the pandemic, a rapid and massive effort has been performed by the scientific community to develop a safe and effective vaccine against SARS-CoV-2.2 In Italy, the first population to receive the vaccine was healthcare workers (HCWs) who are principally exposed to SARS-CoV-2 infection during the management of coronavirus disease 2019 (COVID-19) patients.3 Several doubts remain concerning the neutralizing properties of antibodies produced after vaccination.4 Moreover, little is known about transient infections in vaccinated individuals who therefore could be potential carriers of the disease.5 Finally, it is important to understand the actual efficacy of the approved vaccines against SARS-CoV-2 variants, which have led to enhanced virus transmissibility, morbidity, and mortality.6,7 Here, we report several asymptomatic and vaccinated HCWs who tested positive for SARS-CoV-2 during surveillance testing. [...]all of the cases we observed in this report were due B.1.1.7 lineage infection. [...]although further data and observations of larger cohorts are needed, we strongly believe that continued attention should be devoted to the problem of infection in vaccinated people. |
| doi_str_mv | 10.1017/ice.2021.224 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2730831629</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730831629</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-f6b1c79958b0cf8349fa40d08a5f35b09d07166d44660e836ba5a04ee5ff36fb3</originalsourceid><addsrcrecordid>eNqNkUuLFDEUhYMoTju68wcUuBnRavOoSiWbgaHwBQOCreIupFI3dsaqpCdJ9dD_3jQ9Croyi-TC_c7JvRyEnhO8Jph0b5yBNcWUrCltHqAVaVtZc8Gah2iFhZS1oOz7GXqS0g3GuJOSPEZnjEleTrtCtxvYQ4RKmyVDFSHtXNQ5xENlQgxe711cUnW6aXWxufq8qfvwraYvK-ctmOyCL1Wl02He5TDr7Ey118Y4rzOM1Rb0lLdGly_uQvwJMT1Fj6yeEjy7f8_R13dvv_Qf6utP7z_2V9e1YULm2vKBmDJuKwZsbNlHWt3gEQvdWtYOWI64I5yPTcM5BsH4oFuNG4DWWsbtwM7R5cl3twwzjAZ8jnpSu-hmHQ8qaKf-7ni3VT_CXglKMaa4GFzcG8Rwu0DKanbJwDRpD2FJira0EbxrmCjoi3_Qm7BEX9ZTtGNYMMKpLNTrE2ViSCmC_TMMweqYpSpZqmOWqmRZcHHC72AINhkHvrR_S45hkq6joisVpb3L-phFHxafi_TV_0vZL4GQss4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2730831629</pqid></control><display><type>article</type><title>Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers</title><source>ProQuest Central Essentials</source><source>ProQuest Central (Alumni Edition)</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>ProQuest Central UK/Ireland</source><source>ProQuest Central</source><source>Cambridge University Press Journals Complete</source><creator>Damiani, Verena ; Mandatori, Domitilla ; De Fabritiis, Simone ; Bibbo, Sandra ; Ferrante, Rossella ; Di Giuseppe, Fabrizio ; Ruggieri, Anna Giulia ; Di Camillo, Carola ; Buccolini, Carlotta ; Pizzi, Dora ; Fazii, Paolo ; Stuppia, Liborio ; De Laurenzi, Vincenzo</creator><creatorcontrib>Damiani, Verena ; Mandatori, Domitilla ; De Fabritiis, Simone ; Bibbo, Sandra ; Ferrante, Rossella ; Di Giuseppe, Fabrizio ; Ruggieri, Anna Giulia ; Di Camillo, Carola ; Buccolini, Carlotta ; Pizzi, Dora ; Fazii, Paolo ; Stuppia, Liborio ; De Laurenzi, Vincenzo</creatorcontrib><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused >2.7 million deaths worldwide,1 devasting health systems end economies worldwide. Since the first months of the pandemic, a rapid and massive effort has been performed by the scientific community to develop a safe and effective vaccine against SARS-CoV-2.2 In Italy, the first population to receive the vaccine was healthcare workers (HCWs) who are principally exposed to SARS-CoV-2 infection during the management of coronavirus disease 2019 (COVID-19) patients.3 Several doubts remain concerning the neutralizing properties of antibodies produced after vaccination.4 Moreover, little is known about transient infections in vaccinated individuals who therefore could be potential carriers of the disease.5 Finally, it is important to understand the actual efficacy of the approved vaccines against SARS-CoV-2 variants, which have led to enhanced virus transmissibility, morbidity, and mortality.6,7 Here, we report several asymptomatic and vaccinated HCWs who tested positive for SARS-CoV-2 during surveillance testing. [...]all of the cases we observed in this report were due B.1.1.7 lineage infection. [...]although further data and observations of larger cohorts are needed, we strongly believe that continued attention should be devoted to the problem of infection in vaccinated people.</description><identifier>ISSN: 0899-823X</identifier><identifier>EISSN: 1559-6834</identifier><identifier>DOI: 10.1017/ice.2021.224</identifier><identifier>PMID: 33966665</identifier><language>eng</language><publisher>NEW YORK: Cambridge Univ Press</publisher><subject>Antibodies ; Asymptomatic ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Disease transmission ; Drug dosages ; Genomes ; Health care ; Immunization ; Infections ; Infectious Diseases ; Life Sciences & Biomedicine ; Medical personnel ; Mortality ; Mutation ; Nursing ; Pandemics ; Public, Environmental & Occupational Health ; Research Brief ; Science & Technology ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines</subject><ispartof>Infection control and hospital epidemiology, 2021-11, Vol.42 (11), p.1390-1391, Article 0899823</ispartof><rights>The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Society for Healthcare Epidemiology of America 2021 2021 The Society for Healthcare Epidemiology of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000717728700022</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c389t-f6b1c79958b0cf8349fa40d08a5f35b09d07166d44660e836ba5a04ee5ff36fb3</citedby><cites>FETCH-LOGICAL-c389t-f6b1c79958b0cf8349fa40d08a5f35b09d07166d44660e836ba5a04ee5ff36fb3</cites><orcidid>0000-0002-8043-4807 ; 0000-0002-6232-0996</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2730831629/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2730831629?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,781,785,886,21393,21394,23261,27929,27930,33535,33536,33708,33709,33749,33750,39263,43664,43792,43810,64390,64392,64394,72474,74109,74288,74307</link.rule.ids></links><search><creatorcontrib>Damiani, Verena</creatorcontrib><creatorcontrib>Mandatori, Domitilla</creatorcontrib><creatorcontrib>De Fabritiis, Simone</creatorcontrib><creatorcontrib>Bibbo, Sandra</creatorcontrib><creatorcontrib>Ferrante, Rossella</creatorcontrib><creatorcontrib>Di Giuseppe, Fabrizio</creatorcontrib><creatorcontrib>Ruggieri, Anna Giulia</creatorcontrib><creatorcontrib>Di Camillo, Carola</creatorcontrib><creatorcontrib>Buccolini, Carlotta</creatorcontrib><creatorcontrib>Pizzi, Dora</creatorcontrib><creatorcontrib>Fazii, Paolo</creatorcontrib><creatorcontrib>Stuppia, Liborio</creatorcontrib><creatorcontrib>De Laurenzi, Vincenzo</creatorcontrib><title>Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers</title><title>Infection control and hospital epidemiology</title><addtitle>INFECT CONT HOSP EP</addtitle><description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused >2.7 million deaths worldwide,1 devasting health systems end economies worldwide. Since the first months of the pandemic, a rapid and massive effort has been performed by the scientific community to develop a safe and effective vaccine against SARS-CoV-2.2 In Italy, the first population to receive the vaccine was healthcare workers (HCWs) who are principally exposed to SARS-CoV-2 infection during the management of coronavirus disease 2019 (COVID-19) patients.3 Several doubts remain concerning the neutralizing properties of antibodies produced after vaccination.4 Moreover, little is known about transient infections in vaccinated individuals who therefore could be potential carriers of the disease.5 Finally, it is important to understand the actual efficacy of the approved vaccines against SARS-CoV-2 variants, which have led to enhanced virus transmissibility, morbidity, and mortality.6,7 Here, we report several asymptomatic and vaccinated HCWs who tested positive for SARS-CoV-2 during surveillance testing. [...]all of the cases we observed in this report were due B.1.1.7 lineage infection. [...]although further data and observations of larger cohorts are needed, we strongly believe that continued attention should be devoted to the problem of infection in vaccinated people.</description><subject>Antibodies</subject><subject>Asymptomatic</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Disease transmission</subject><subject>Drug dosages</subject><subject>Genomes</subject><subject>Health care</subject><subject>Immunization</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Life Sciences & Biomedicine</subject><subject>Medical personnel</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Nursing</subject><subject>Pandemics</subject><subject>Public, Environmental & Occupational Health</subject><subject>Research Brief</subject><subject>Science & Technology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><issn>0899-823X</issn><issn>1559-6834</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkUuLFDEUhYMoTju68wcUuBnRavOoSiWbgaHwBQOCreIupFI3dsaqpCdJ9dD_3jQ9Croyi-TC_c7JvRyEnhO8Jph0b5yBNcWUrCltHqAVaVtZc8Gah2iFhZS1oOz7GXqS0g3GuJOSPEZnjEleTrtCtxvYQ4RKmyVDFSHtXNQ5xENlQgxe711cUnW6aXWxufq8qfvwraYvK-ctmOyCL1Wl02He5TDr7Ey118Y4rzOM1Rb0lLdGly_uQvwJMT1Fj6yeEjy7f8_R13dvv_Qf6utP7z_2V9e1YULm2vKBmDJuKwZsbNlHWt3gEQvdWtYOWI64I5yPTcM5BsH4oFuNG4DWWsbtwM7R5cl3twwzjAZ8jnpSu-hmHQ8qaKf-7ni3VT_CXglKMaa4GFzcG8Rwu0DKanbJwDRpD2FJira0EbxrmCjoi3_Qm7BEX9ZTtGNYMMKpLNTrE2ViSCmC_TMMweqYpSpZqmOWqmRZcHHC72AINhkHvrR_S45hkq6joisVpb3L-phFHxafi_TV_0vZL4GQss4</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Damiani, Verena</creator><creator>Mandatori, Domitilla</creator><creator>De Fabritiis, Simone</creator><creator>Bibbo, Sandra</creator><creator>Ferrante, Rossella</creator><creator>Di Giuseppe, Fabrizio</creator><creator>Ruggieri, Anna Giulia</creator><creator>Di Camillo, Carola</creator><creator>Buccolini, Carlotta</creator><creator>Pizzi, Dora</creator><creator>Fazii, Paolo</creator><creator>Stuppia, Liborio</creator><creator>De Laurenzi, Vincenzo</creator><general>Cambridge Univ Press</general><general>Cambridge University Press</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8043-4807</orcidid><orcidid>https://orcid.org/0000-0002-6232-0996</orcidid></search><sort><creationdate>20211101</creationdate><title>Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers</title><author>Damiani, Verena ; Mandatori, Domitilla ; De Fabritiis, Simone ; Bibbo, Sandra ; Ferrante, Rossella ; Di Giuseppe, Fabrizio ; Ruggieri, Anna Giulia ; Di Camillo, Carola ; Buccolini, Carlotta ; Pizzi, Dora ; Fazii, Paolo ; Stuppia, Liborio ; De Laurenzi, Vincenzo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-f6b1c79958b0cf8349fa40d08a5f35b09d07166d44660e836ba5a04ee5ff36fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Asymptomatic</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Disease transmission</topic><topic>Drug dosages</topic><topic>Genomes</topic><topic>Health care</topic><topic>Immunization</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Life Sciences & Biomedicine</topic><topic>Medical personnel</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Nursing</topic><topic>Pandemics</topic><topic>Public, Environmental & Occupational Health</topic><topic>Research Brief</topic><topic>Science & Technology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Damiani, Verena</creatorcontrib><creatorcontrib>Mandatori, Domitilla</creatorcontrib><creatorcontrib>De Fabritiis, Simone</creatorcontrib><creatorcontrib>Bibbo, Sandra</creatorcontrib><creatorcontrib>Ferrante, Rossella</creatorcontrib><creatorcontrib>Di Giuseppe, Fabrizio</creatorcontrib><creatorcontrib>Ruggieri, Anna Giulia</creatorcontrib><creatorcontrib>Di Camillo, Carola</creatorcontrib><creatorcontrib>Buccolini, Carlotta</creatorcontrib><creatorcontrib>Pizzi, Dora</creatorcontrib><creatorcontrib>Fazii, Paolo</creatorcontrib><creatorcontrib>Stuppia, Liborio</creatorcontrib><creatorcontrib>De Laurenzi, Vincenzo</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection control and hospital epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Damiani, Verena</au><au>Mandatori, Domitilla</au><au>De Fabritiis, Simone</au><au>Bibbo, Sandra</au><au>Ferrante, Rossella</au><au>Di Giuseppe, Fabrizio</au><au>Ruggieri, Anna Giulia</au><au>Di Camillo, Carola</au><au>Buccolini, Carlotta</au><au>Pizzi, Dora</au><au>Fazii, Paolo</au><au>Stuppia, Liborio</au><au>De Laurenzi, Vincenzo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers</atitle><jtitle>Infection control and hospital epidemiology</jtitle><stitle>INFECT CONT HOSP EP</stitle><date>2021-11-01</date><risdate>2021</risdate><volume>42</volume><issue>11</issue><spage>1390</spage><epage>1391</epage><pages>1390-1391</pages><artnum>0899823</artnum><issn>0899-823X</issn><eissn>1559-6834</eissn><abstract>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused >2.7 million deaths worldwide,1 devasting health systems end economies worldwide. Since the first months of the pandemic, a rapid and massive effort has been performed by the scientific community to develop a safe and effective vaccine against SARS-CoV-2.2 In Italy, the first population to receive the vaccine was healthcare workers (HCWs) who are principally exposed to SARS-CoV-2 infection during the management of coronavirus disease 2019 (COVID-19) patients.3 Several doubts remain concerning the neutralizing properties of antibodies produced after vaccination.4 Moreover, little is known about transient infections in vaccinated individuals who therefore could be potential carriers of the disease.5 Finally, it is important to understand the actual efficacy of the approved vaccines against SARS-CoV-2 variants, which have led to enhanced virus transmissibility, morbidity, and mortality.6,7 Here, we report several asymptomatic and vaccinated HCWs who tested positive for SARS-CoV-2 during surveillance testing. [...]all of the cases we observed in this report were due B.1.1.7 lineage infection. [...]although further data and observations of larger cohorts are needed, we strongly believe that continued attention should be devoted to the problem of infection in vaccinated people.</abstract><cop>NEW YORK</cop><pub>Cambridge Univ Press</pub><pmid>33966665</pmid><doi>10.1017/ice.2021.224</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-8043-4807</orcidid><orcidid>https://orcid.org/0000-0002-6232-0996</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0899-823X |
| ispartof | Infection control and hospital epidemiology, 2021-11, Vol.42 (11), p.1390-1391, Article 0899823 |
| issn | 0899-823X 1559-6834 |
| language | eng |
| recordid | cdi_proquest_journals_2730831629 |
| source | ProQuest Central Essentials; ProQuest Central (Alumni Edition); Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; ProQuest Central UK/Ireland; ProQuest Central; Cambridge University Press Journals Complete |
| subjects | Antibodies Asymptomatic Coronaviruses COVID-19 COVID-19 vaccines Disease transmission Drug dosages Genomes Health care Immunization Infections Infectious Diseases Life Sciences & Biomedicine Medical personnel Mortality Mutation Nursing Pandemics Public, Environmental & Occupational Health Research Brief Science & Technology Severe acute respiratory syndrome coronavirus 2 Vaccines |
| title | Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T09%3A26%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20acute%20respiratory%20coronavirus%20virus%202%20(SARS-CoV-2)%20infection%20in%20asymptomatic%20vaccinated%20healthcare%20workers&rft.jtitle=Infection%20control%20and%20hospital%20epidemiology&rft.au=Damiani,%20Verena&rft.date=2021-11-01&rft.volume=42&rft.issue=11&rft.spage=1390&rft.epage=1391&rft.pages=1390-1391&rft.artnum=0899823&rft.issn=0899-823X&rft.eissn=1559-6834&rft_id=info:doi/10.1017/ice.2021.224&rft_dat=%3Cproquest_cross%3E2730831629%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2730831629&rft_id=info:pmid/33966665&rfr_iscdi=true |